6:29 PM
 | 
Oct 08, 2015
 |  BC Extra  |  Clinical News

Neurocrine gains on Phase III dyskinesia data

Neurocrine Biosciences Inc. (NASDAQ:NBIX) gained $4.67 (12%) to $43.60 after its NBI-98854 met the primary endpoint in the Phase III Kinect 3 trial to treat tardive dyskinesia. Daily 80 mg doses of NBI-98854 significantly reduced involuntary movement at week six, reducing scores from...

Read the full 202 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >